Wegovy 7.2 mg: the UK release dates and what the approval means for you

The two approval milestones and why the timeline matters

Understanding the Wegovy 7.2 mg story requires keeping two dates apart, because they mark different things. In January 2026, the MHRA approved 7.2 mg as a licensed maintenance dose, but at that point it was only achievable by administering three separate 2.4 mg pens in a single week. That was an interim arrangement, not a long-term solution. The dedicated single-dose 7.2 mg pen, with an auto-dosing mechanism, built-in covered needle and a lock that activates after use, received MHRA approval on 14 April 2026. The UK was among the earliest countries to have this option approved.

The distinction matters practically. The three-pen interim method required patients to manage additional pens and injection events each week, and availability depended on a prescriber arranging that regimen specifically. The single-dose pen simplifies that to one weekly injection, identical in routine to the lower doses. If you are reading about Wegovy 7.2 mg and wondering whether it is currently an option, the practical details around the 7.2 mg pen give a clearer picture of what is available and under what conditions a prescriber would consider it.

One quick check worth doing: the MHRA's approval is publicly documented on GOV.UK. Searching the official MHRA announcement for the 7.2 mg pen takes under a minute and confirms the approval date, the licensed population, and the pen's technical specification directly from the regulator, useful when evaluating claims from any provider.

What the trial evidence showed at this dose level

The appetite for a higher-dose option grew from a clear clinical question: could more of the medicine produce meaningfully better outcomes? The data suggests yes. Trials at 7.2 mg reported approximately 20.7% average weight loss over 72 weeks, a figure that begins to overlap with the results seen in tirzepatide studies, particularly the SURMOUNT-1 data published in the New England Journal of Medicine, where the highest tirzepatide dose produced around 20–21% average weight reduction. The head-to-head SURMOUNT-5 trial, also published in the NEJM in 2025, had already shown tirzepatide producing greater average loss than semaglutide 2.4 mg; the 7.2 mg data narrows that gap considerably.

That narrowing is clinically significant. Some patients do not tolerate tirzepatide, prefer an injection-only GLP-1 pathway, or have other clinical reasons to remain on semaglutide. For them, the 7.2 mg option now exists where it did not before 2026. The full Wegovy dose range covers how each step in the schedule works and what the prescriber is weighing at each stage. Side effects at higher doses are worth understanding before any decision, and the profile at 7.2 mg broadly follows the gastrointestinal pattern seen at lower strengths; the side effects specific to the 7.2 mg level go into that in detail.

Who the 7.2 mg approval applies to, and who it does not

The MHRA's approval of the dedicated 7.2 mg pen carries a specific licensed population: adults with a BMI of 30 or above. That is a narrower frame than the broader Wegovy weight-management licence, which extends to adults with a BMI of 27–29.9 alongside at least one weight-related condition. The 7.2 mg pen is not authorised for that lower BMI range, and it is not licensed for the cardiovascular risk-reduction indication that Wegovy also holds in the UK.

The titration path also remains unchanged. Treatment starts at 0.25 mg regardless of which maintenance dose a patient may ultimately reach; the prescriber steps through the schedule at roughly four-week intervals. A patient does not begin at 7.2 mg. That context is worth holding when reading marketing from any provider: the date of approval is one fact; when and whether a specific individual reaches that dose is a separate clinical question entirely. For a grounded sense of how the full Wegovy programme fits together, the dose schedule explains each stage plainly. Patients considering whether Wegovy or an alternative like tirzepatide better fits their situation may also find it useful to read about semaglutide at 7.2 mg in broader clinical context.

Private access and what to consider before starting

Wegovy is not available without a prescription. In England, NHS access under NICE's appraisal of semaglutide (TA875) is routed through specialist weight management services with multidisciplinary support; waiting lists are long in most areas, and the 7.2 mg dose within that pathway will follow local clinical protocols. Private prescribing is the practical route for most people who want to start sooner, which is where a service like Wegovy through a regulated pharmacy becomes relevant.

Cost is a real factor. The cost of Wegovy in the UK varies by dose and provider, and the price picture changed after Eli Lilly's widely reported list-price revision in September 2025 for tirzepatide, shifting the competitive landscape for semaglutide too. Any legitimate price for a prescription medicine should include clinical assessment, not just the pen.

If 7.2 mg, or Wegovy at any dose, feels like something worth exploring, a consultation with a GPhC-registered prescriber is the place to start. Our prescribers review every consultation personally, the same day for orders placed before noon Monday to Friday. Start your free consultation to find out whether Wegovy is clinically suitable for you and, if so, where in the dose schedule it makes sense to begin.